Merck reported strong first-quarter performance with double-digit sales and EPS growth, exceeding expectations and raising full-year guidance. The robust performance of KEYTRUDA and significant growth in international markets, especially China, coupled with a positive management outlook, suggest continued investor confidence in the short term.

[1]